All In Biotech

NDA 216386 · Pfizer

Zavzpret

Zavegepant Hydrochloride · Nasal

Novel

CDER novel approval, Mar 9, 2023: To treat migraine

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Mar 9, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

17

6 Phase 3, 3 recruiting

FAERS reports

892

83 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 26, 2025.

ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ( 1 )

Mechanism: Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 9, 2023 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • ZAVZPRET · ZAVEGEPANT HYDROCHLORIDE EQ 10MG BASE/SPRAY · SPRAY, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Zavegepant" as an intervention, any sponsor and status, largest first.

All 17 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dysgeusia259
  • drug ineffective147
  • nasal discomfort85
  • nausea81
  • throat irritation75
  • vomiting71
  • migraine45
  • therapeutic product effect incomplete44
  • headache38
  • off label use36
  • taste disorder36
  • burning sensation31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2023236
2024266
2025248
2026142

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zavzpret (Zavegepant HCl)

2024 spending

$8.9M

Beneficiaries

2,783

7,727 claims

Per beneficiary

$3,209

$177.46 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$2,306,719
2024$8,929,258

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.